Nyathi S, Dlodlo RA, Satyanarayana S, Takarinda KC, Tweya H, Hove S, et al. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe. PLoS ONE. 2019;14(10):e0223076.
MOH. National Comprehensive TBLand TB/HIV training Manual. 2021.
Aboma M, Dida N. Tuberculosis screening coverage and isoniazid preventive therapy among people living with HIV at Gambella Hospital, Southwest Ethiopia: a retrospective study design. J Int Med Res. 2021;49(9):3000605211046133.
Sabasaba A, Mwambi H, Somi G, Ramadhani A, Mahande MJ. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study. BMC Infect Dis. 2019;19(1):62.
FMoHo E. National consolidated guidelines for comprehensive HIV prevention, care and treatment. August;2018.
Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC Public Health. 2015;15:346.
Dhungana GP, Thekkur P, Chinnakali P, Bhatta U, Pandey B, Zhang W-H. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study. BMJ open. 2019;9(5):e029058.
Legese H, Degefa H, Gebrewahd A, Gebremedhin H. Utilization of isoniazid prophylaxis therapy and its associated factors among HIV positive clients taking antiretroviral therapy at Fre Semaetat primary hospital, Hawzien districts, Tigrai, Northern Ethiopia. Tropical diseases, travel medicine and vaccines. 2020;6:11.
Ngugi SK, Muiruri P, Odero T, Gachuno O. Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study. BMC Infect Dis. 2020;20(1):294.
Robert M, Todd J, Ngowi BJ, Msuya SE, Ramadhani A, Sambu V, et al. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar Es Salaam Region, Tanzania. A cross-sectional analytical study. BMC Infect Dis. 2020;20(1):276.
Organization Wh. WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment – Drug-Resistant Tuberculosis Treatment. 2022.
Takarinda KC, Choto RC, Harries AD, Mutasa-Apollo T, Chakanyuka-Musanhu C. Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe. Public Health Action. 2017;7(1):55–60.
Lim C, Wong P, Pereirasamy L, Ang P, Leong K, Chow T. Outcome of isoniazid preventive therapy in adults living with HIV in Penang, Malaysia. J Infect Dis Prev Med. 2016;4:2.
Adams LV, Mahlalela N, Talbot EA, Pasipamire M, Ginindza S, Calnan M, et al. High completion rates of isoniazid preventive therapy among persons living with HIV in Swaziland. Int J Tuberculosis lung Disease: Official J Int Union against Tuberculosis Lung Disease. 2017;21(10):1127–32.
Hawken MP, Muhindi DW. Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries. Int J Tuberculosis lung Disease: Official J Int Union against Tuberculosis Lung Disease. 1999;3(8):646–50.
Ayele AA, Asrade Atnafie S, Balcha DD, Weredekal AT, Woldegiorgis BA, Wotte MM, et al. Self-reported adherence and associated factors to isoniazid preventive therapy for latent tuberculosis among people living with HIV/AIDS at health centers in Gondar town, North West Ethiopia. Patient Prefer Adherence. 2017;11:743–9.
Berhe M, Demissie M, Tesfaye G. Isoniazid preventive therapy adherence and associated factors among HIV positive patients in Addis Ababa, Ethiopia. Adv Epidemiol. 2014;2014.
Hermans SM, Castelnuovo B, Katabira C, Mbidde P, Lange JM, Hoepelman AI, et al. Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda. JAIDS J Acquir Immune Defic Syndr. 2012;60(2):e29–35.
Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8(1):e1000391.
Kakaire R. Risk for latent tuberculosis infection among household and non-household contacts of TB cases in an urban African setting. University of Georgia; 2018.
Dadi TK, Feyasa MB, Gebre MN. HIV Voluntary Counseling and Testing Uptake and Associated Factors among sexually active men in Ethiopia: evidence from the 2016 EDHS using Multilevel modeling. 2020.
Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, et al. Advances in Tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013;13(4):349–61.
Reddy MM, Thekkur P, Ramya N, Kamath PB, Shastri SG, Kumar RB, et al. To start or to complete?–Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India. Global Health Action. 2020;13(1):1704540.
Add Comment